The News
KALA BIO, Inc. has announced a strategic initiative to develop an on-premises AI infrastructure platform tailored for the biotech industry. The company has entered into a platform development and exclusive license agreement for its proprietary AI research platform, named 'Researgenc'.
Why It Matters
This initiative signifies a growing trend of integrating AI into the biotech sector, potentially enhancing research capabilities and operational efficiencies. By establishing a dedicated AI infrastructure, KALA BIO aims to leverage advanced technologies to accelerate drug development and improve outcomes in biopharmaceutical research.
Key Evidence
The information is derived from an official announcement by KALA BIO, published via Globe Newswire, indicating a reliable source.